New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:31 EDTKERX, AMRNKeryx slide attributable to Zerenex market exclusivity worries, The Street says
The 22% decline in Keryx Pharmaceuticals (KERX) seen on Friday was attributable to concerns raised by a report from IPD Analytics about the company's ability to gain FDA "New Chemical Entity" status for Zerenex, according to The Street's Adam Feuerstein. The author notes that Amarin (AMRN) shares are sometimes volatile over a similar concern, namely that a key drug may not be able to secure NCE status, which grants five years of market exclusivity for a unique pharmaceutical compound. Reference Link
News For KERX;AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
09:16 EDTKERXKeryx Auryxia outlook still positive, says Roth Capital
Subscribe for More Information
February 27, 2015
09:24 EDTKERXOn The Fly: Pre-market Movers
Subscribe for More Information
08:52 EDTKERXKeryx CFO to leave company by October
Keryx Biopharmaceuticals disclosed in a regulatory filing a planned consolidation of its finance and accounting function into its Boston office and that its CFO, James Oliviero, will be leaving Keryx by October. In connection with this transition, the company entered into an employment agreement with Oliviero that became effective on February 26 and will terminate on October 1, but may be extended upon the mutual agreement of the parties. The company has commenced a search for a new CFO who will be based in its Boston office. Oliviero will continue to manage the company’s finance and accounting team during the remainder of his tenure and will assist in the transition of his duties to the new CFO, Keryx said.
07:14 EDTKERXKeryx reports Q4 EPS (44c), consensus (37c)
Subscribe for More Information
February 26, 2015
09:23 EDTAMRNAmarin, Eddingpharm agree to develop, commercialize Vascepa in China
Amarin Corporation and Eddingpharm announced an exclusive agreement for Eddingpharm to develop and commercialize Vascepa in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan for uses that are currently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa. Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169M, including a non-refundable $15M up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154M. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.
09:00 EDTAMRNAmarin trading halted, pending news
Subscribe for More Information
February 20, 2015
16:03 EDTAMRNOptions Update; February 20, 2015
Subscribe for More Information
10:20 EDTAMRNHigh option volume stocks
Subscribe for More Information
09:38 EDTAMRNActive equity options trading on open
Subscribe for More Information
February 18, 2015
10:05 EDTAMRNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
09:10 EDTAMRNOn The Fly: Pre-market Movers
Subscribe for More Information
06:05 EDTAMRNAmarin upgraded to Buy from Neutral at SunTrust
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use